PT  - JOURNAL ARTICLE
AU  - Boltz, Kathy
ED  - Paz-Ares, Luis
ED  - Novello, Silvia
ED  - Goss, Glendwood D.
TI  - ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 5--6
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/5.short
4100  - http://mdc.sagepub.com/content/15/8/5.full
AB  - The subgroup of patients with the EGFR-activating mutation in exon 19 or 21 appeared to have a favorable trend for dacomitinib vs erlotinib in progression-free survival. Afatinib was favored over erlotinib for second-line treatment of advanced squamous cell carcinoma in terms of progression-free survival, overall response rate, and disease control rate.